EditorialPublished 10 Nov 2017
The newest medicine: Chimeric antigen receptor T-Cell immunotherapy (CAR-T)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recent approval of chimeric antigen receptor T-cell immunotherapy (CAR-T) for the clinical use represents a significant progress in the human defense war against cancer, and validates a novel bio-pharmaceutical platform that synergizes the strengths of adoptive cellular immunotherapy as well as molecular genetic engineering. With the curable efficacy for refractory B-cell malignancy, CAR-T is increasingly contributing to a paradigm shift toward immunotherapy in oncologic medicine and pharmaceutical innovation. Through optimization of the relevant bio-technological aspects with timely translation from science to medicine, CAR-T pipeline is expected to go beyond hematological application, to deliver additional therapeutic benefits to the patients with solid tumors.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Translational Research
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Daohong Chen”
